Missed this before I could edit my previous message
---
An early patient experience program is expected to be launched by Botanix in the third quarter of this calendar year to allow highly-qualified patients to gain early access to Sofdra.
The broader launch of Sofdra is expected to follow early in the fourth quarter, with first revenues from sales expected in the period.
---
Who or what is a highly-qualified patient?
Missed this before I could edit my previous message---An early...
-
- There are more pages in this discussion • 303 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $678.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.3¢ | $1.835M | 4.963M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13513 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 25681 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |